Cordis DAPT Cypress
At present it is the standard of care to have patients with stents take dual antiplatelet therapy for twelve months. The two therapies usually include Plavix and aspirin. The question to be examined is whether there is a benefit to continuing these therapies beyond 12 months. This study will enroll approximately 2,000 patients at 200 centers across the country. Twelve months after the implant of the CYPHER stent, the patients who remain free of complications (heart attack, stroke, restenosis, stent thrombosis, major bleeding, death) will be randomized to two groups: placebo or an additional 18 months of thienopyridine therapy. Click here to read more

ELA Prediction
Click here to learn more

ELA Ovatio
Post approval study measuring safety outcomes on the Ovatio CRT-D and SITUS OTW LV lead over 5 years.
Click here to learn more

Biotronik Celestial
This post market study will enroll and follow approximately 2000 subjects implanted with Biotronik's Corox OTW(-S) BP LV lead with a Biotronik CRT device from implant to 5 years to confirm the reliability and safety of FDA approved ventricular and pacing leads.
Click here to learn more

Biotronik Galaxy
This post market, multi-center study is non-randomized and will collect data from implant of the Linox Lead System connected to a Biotronik ICD to confirm the safety and efficacy on FDA approved leads.
Click here to learn more